Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours

Author： Bourgeois H.   Vermorken J.   Dark G.   Jones A.   Fumoleau P.   Stupp R.   Tourani J.   Brain E.   Nguyen L.   Lefresne F.   Puozzo C.  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.60, Iss.3, 2007-08, pp. : 407-413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

By Trocòniz Iñaki   Garrido María   Segura Cristina   Cendrós Josep-María   Principe Paola   Peraire Concepción   Obach Rosendo  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 727-735

Springer Publishing Company

Access to resources Recommend Favorite

Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

By Dueland Svein   Aamdal Steinar   Lind Michael   Thomas Hilary   Liland Sandvold Marit   Gaullier Jean-Michel   Rasch Wenche  

Acta Oncologica, Vol. 48, Iss. 1, 2009-01 ,pp. : 137-145

Informa Healthcare

Access to resources Recommend Favorite

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

By Deporte-Fety R.   Simon N.   Fumoleau P.   Campone M.   Kerbrat P.   Bonneterre J.   Fargeot P.   Urien S.  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 3, 2004-03 ,pp. : 233-238

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

By Crul M.   Rosing H.   de Klerk G.J.   Dubbelman R.   Traiser M.   Reichert S.   Knebel N.G.   Schellens J.H.M.   Beijnen J.H.   ten Bokkel Huinink W.W.  

European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. : 1615-1621

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

By Awada A.   Eskens F.A.L.M.   Piccart M.   Cutler D.L.   van der Gaast A.   Bleiberg H.   Wanders J.   Faber M.N.   Statkevich P.   Fumoleau P.   Verweij J.   for the EORTC Early Clinical Studies Group  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2272-2278

Elsevier

Access to resources Recommend Favorite